VBL Therapeutics’ Investigational Drug Ofra-Vec Fails Phase 3 Trial
VBL Therapeutics’ investigational drug ofra-vec (ofranergene obadenovec; VB-111) failed to show promise in a late-stage study for treatment of platinum-resistant ovarian cancer.
In the phase 3 trial, the combined ofra-vec plus paclitaxel treatment did not show meaningful improvements in progression-free survival and overall survival, the study’s primary endpoints.
VBL has decided to discontinue the study and shift its focus to ongoing phase 2 clinical trials to determine ofra-vec’s possible uses in metastatic colorectal cancer and recurrent glioblastoma multiforme.
“Given the urgent unmet need for those fighting platinum-resistant ovarian cancer, we are deeply disappointed that the top-line data indicate that ofra-vec did not improve progression free survival or overall survival,” said VBL CEO Dror Harats.
VBL Therapeutics
Israeli company called Vascular Biogenics, also called VBL Therapeutics. The company was founded in 2000. VBL is a biotechnology company using the molecular machinery of the body to precisely address disease. Proprietary gene-targeting and antibody technologies were designed to provide. VBL is a biotechnology company using the molecular machinery of the body to precisely address disease.
VBL Therapeutics is a publicly traded (NASDAQ: VBLT), clinical stage biotechnology company committed to the discovery, development and commercialization of next-generation, targeted medicines for difficult-to-treat medical conditions. Goal is to develop and provide safe, effective and life-improving medicines to people living with cancer and immune-inflammatory diseases.
July 21, 2022
